News

<>

April 15, 2017

BioCentury

WAC-A-MOL

By Stephen Hansen

While investors, media and even some payers have been touting the pricing of three recently launched drugs as
sensible, it is not clear whether the lower-than-expected list prices will actually reduce costs to payers. But they
are likely to result in lower co-pays for patients, which could increase access.

read full article >